Key TakeawaysAbbVie reduced its current quarter outlook related to costs from its acquisition of ImmunoGen.The drug maker announced the $10.1 billion purchase in November, giving it access to ImmunoGen's key ovarian cancer treatment.AbbVie reiterated its full-year outlook, taking into account effects of its purchase of Immunogen and pending acquisition of Cerevel Therapeutics.Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.AbbVie red ...